Pfizer currently manufactures six FDA-approved vaccines, covering COVID-19, pneumococcal disease, RSV, meningococcal disease, and tick-borne encephalitis. The company is one of the largest vaccine makers in the world, with its vaccine portfolio generating over $11 billion in revenue in 2024 alone.
COVID-19: Comirnaty
Comirnaty is Pfizer’s mRNA-based COVID-19 vaccine, developed in partnership with BioNTech. It was the first COVID-19 vaccine to receive full FDA approval and remains one of the most widely administered vaccines globally. The formula is updated annually to match circulating variants. For fall 2025, the FDA has directed manufacturers to use a JN.1-lineage composition, preferentially targeting the LP.8.1 strain. Comirnaty brought in $5.35 billion in revenue for Pfizer in 2024.
Pneumococcal Disease: Prevnar 20
Prevnar 20 protects against 20 types of pneumococcal bacteria, which cause pneumonia, meningitis, and bloodstream infections. It replaced the earlier Prevnar 13, which covered 13 types. The number at the end of the name corresponds to how many bacterial strains the vaccine targets.
Prevnar 20 is given to children under 5, older children with certain risk factors, and adults 50 and older. Younger adults with conditions that weaken the immune system may also receive it. The Prevnar family is actually Pfizer’s highest-earning vaccine product, generating $6.41 billion in 2024.
RSV: Abrysvo
Abrysvo protects against respiratory syncytial virus, a common respiratory infection that can be dangerous for newborns and older adults. What makes this vaccine unusual is its dual indication: it can be given to pregnant women or to older adults.
For pregnant women, the CDC recommends a single dose between 32 and 36 weeks of gestation. The mother’s immune response passes protective antibodies to the baby before birth, shielding the infant during the first months of life when RSV poses the greatest risk. Older adults receive their own dose for direct protection.
Meningococcal Disease: Penbraya and Trumenba
Pfizer makes two vaccines targeting meningococcal disease, a rare but potentially fatal bacterial infection that strikes quickly and disproportionately affects teenagers and young adults.
Penbraya is a combination vaccine that covers five serogroups of meningococcal bacteria: A, B, C, W, and Y. Before combination vaccines like Penbraya existed, protecting against all five serogroups required separate shots. Penbraya simplifies that into a single product.
Trumenba targets serogroup B specifically. It is given as either a two-dose series (spaced six months apart) or a three-dose series for people who need faster protection, such as college students heading to campus in less than six months. A three-dose schedule spaces the shots at zero, one to two months, and six months.
Tick-Borne Encephalitis: TicoVac
TicoVac protects against tick-borne encephalitis, a viral infection transmitted through tick bites that can cause serious brain inflammation. It is approved for anyone aged 1 year and older. The vaccine has been used in Europe for over 20 years and is available in many countries where the virus circulates. It received FDA approval in August 2021, making it relevant mainly for travelers heading to endemic areas in Europe and Asia.
Vaccines in Development
Pfizer is applying its mRNA technology beyond COVID-19. A phase 3 trial of an mRNA-based seasonal flu vaccine, published in the New England Journal of Medicine, tested the shot in more than 18,000 adults aged 18 to 64. In a flu season dominated by influenza A, the mRNA version showed roughly 29% better efficacy than a standard inactivated flu vaccine and generated stronger antibody and immune cell responses against key influenza strains. The tradeoff was higher reactogenicity: 5.6% of recipients developed a fever compared to 1.7% with the conventional shot, though symptoms were generally mild to moderate.
Pfizer also has a phase 3 trial underway for a maternal vaccine against Group B Streptococcus, a bacterium that can pass from mother to baby during delivery and cause serious infections in newborns. The trial, called BEATRIX, enrolls healthy pregnant women between 24 and 36 weeks of gestation. If successful, it would follow the same strategy as Abrysvo: vaccinate the mother to protect the infant.